Chryseobacterium/Elizabethkingia species infections in Saudi Arabia

Saudi Med J. 2020 Mar;41(3):309-313. doi: 10.15537/smj.2020.3.24985.


Objectives: To describe the epidemiological, clinical, and outcome data of patients infected or colonized with Chryseobacterium/Elizabethkingia spp including antibiotic susceptibility patterns.

Methods: This retrospective study was conducted at Prince Sultan Military Medical City, Riyadh, Saudi Arabia. All patients infected or colonized by Chryseobacterium /Elizabethkingia spp who were admitted between June 2013 and May 2019 were included. Data were extracted from patient electronic medical records.

Results: We enrolled 27 patients (13 males and 14 females) with a mean age of 35.6 years. Chryseobacterium/Elizabethkingia spp were isolated from blood cultures (n=13, 48%) and tracheal aspirations (n=11, 41%). The most frequent species isolated was Elizabethkingia meningoseptica (n=22). Although 6 patients were considered colonized, the remaining 21 patients presented with ventilator associated pneumonia (n=9), central line associated bloodstream infection (n=4), septic shock (n=4), or isolated bacteremia (n=4). In 25 cases the infections were health-care related. Three patients (11%) died within 28 days. Twenty-six isolates (96.5%) were resistant to carbapenems. Moxifloxacin and cotrimoxazole were the most active antibiotics.

Conclusion: Chryseobacterium/Elizabethkingia spp infection is rare, but can be responsible for severe hospital acquired infections. Cotrimoxazole and fluoroquinolone are the most effective antibiotic treatments.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Child
  • Child, Preschool
  • Chryseobacterium / drug effects
  • Chryseobacterium / isolation & purification
  • Drug Resistance, Bacterial
  • Female
  • Flavobacteriaceae Infections / drug therapy
  • Flavobacteriaceae Infections / epidemiology*
  • Flavobacteriaceae Infections / microbiology*
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Middle Aged
  • Moxifloxacin / pharmacology
  • Moxifloxacin / therapeutic use
  • Retrospective Studies
  • Saudi Arabia / epidemiology
  • Trimethoprim, Sulfamethoxazole Drug Combination / pharmacology
  • Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use
  • Young Adult


  • Anti-Bacterial Agents
  • Trimethoprim, Sulfamethoxazole Drug Combination
  • Moxifloxacin

Supplementary concepts

  • Chryseobacterium indologenes